Compare Advance Auto Parts, Inc. (AAP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs TG Therapeutics Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.94 (market cap $3.19B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 2.4× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AAP | TGTX | |
|---|---|---|
Market Cap | $3.19B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $59.06 |
52-Week Low | $38.75 | $26.94 |
Enterprise Value | $5.47B | $7.84B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.52, down 3.97% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.77 versus $0.39 expected, but profitability remains thin with a net income margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain improvements, as noted in recent news (The Motley Fool, August 2026).
The outlook is cautious; while valuation appears reasonable with a P/S of 0.37 and analysts set a $61.30 consensus target, weak cash flow from operations and high debt pose risks. Investor sentiment is neutral amid restructuring efforts, but margin expansion and successful execution are critical for sustained recovery.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
